Patrick Trucchio

Patrick Trucchio Analyst Performance

Managing Director of Equity Research at HC Wainwright

Patrick Trucchio is a stock analyst at HC Wainwright focused in the medical sector, covering 27 publicly traded companies. Over the past year, Patrick Trucchio has issued 12 stock ratings, including and buy recommendations. While full access to Patrick Trucchio's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Patrick Trucchio's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
129 Last 7 Years
Buy Recommendations
98.41% 124 Buy Ratings
Companies Covered
27 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy98.4%124 ratings
Hold1.6%2 ratings
Sell0.0%0 ratings

Out of 126 total stock ratings issued by Patrick Trucchio at HC Wainwright, the majority (98.4%) have been Buy recommendations, followed by 1.6% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
81.5% of companies on NASDAQ
22 companies
NYSE
7.4% of companies on NYSE
2 companies
TSE
7.4% of companies on TSE
2 companies
OTCMKTS
3.7% of companies on OTCMKTS
1 company

Patrick Trucchio, an analyst at HC Wainwright, currently covers 27 companies listed on NASDAQ, NYSE, TSE and OTCMKTS, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
26 companies
96.3%
Manufacturing
1 company
3.7%

Patrick Trucchio of HC Wainwright specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
15 companies
55.6%
MED - DRUGS
3 companies
11.1%
BIOTECHNOLOGY
3 companies
11.1%
MED - GENERIC DRG
1 company
3.7%
MEDICAL SERVICES
1 company
3.7%
MED - OUTP/HM CRE
1 company
3.7%
Miscellaneous
1 company
3.7%
OUTPATIENT MENTAL HEALTH & SUBSTANCE ABUSE CENTERS
1 company
3.7%
MED PRODUCTS
1 company
3.7%

About Patrick Trucchio

Mr. Trucchio is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on biotechnology, specifically on inflammation, fibrosis, cardio-metabolic, CNS, and rare diseases in addition to other areas. Mr. Trucchio has thirteen years of research experience on the sell-side. Prior to joining H.C. Wainwright, Mr. Trucchio was a senior equity research analyst at Berenberg Capital Markets (BCM) covering biotechnology and specialty pharmaceutical companies. Prior to Berenberg Capital Markets, Mr. Trucchio worked at Wells Fargo Securities and BMO Capital Markets. At Wells Fargo, Mr Trucchio worked on an Institutional Investor ranked analyst team covering specialty pharmaceutical companies. Mr. Trucchio’s educational background includes an M.B.A. with Honors from St. John’s University and a B.S. in Finance from The Pennsylvania State University.
Follow on LinkedIn

Patrick Trucchio's Ratings History at HC Wainwright

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
6/17/2026Reiterated Rating$21.03Buy
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
11/4/2025Set Price Target$434.07$570.00Buy
uniQure N.V. stock logo
QURE
uniQure
11/4/2025Lower Price Target$34.29$70.00Buy
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
8/18/2025Initiated Coverage$25.44$50.00Buy
Altimmune, Inc. stock logo
ALT
Altimmune
8/13/2025Reiterated Rating$3.85$12.00Buy
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
8/7/2025Boost Price Target$428.14$570.00Buy
Compass Pathways PLC Sponsored ADR stock logo
CMPS
Compass Pathways
8/4/2025Lower Price Target$4.73$40.00Buy
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
7/30/2025Reiterated Rating$3.49$15.00Buy
Compass Pathways PLC Sponsored ADR stock logo
CMPS
Compass Pathways
7/15/2025Reiterated Rating$3.64$45.00Buy
Altimmune, Inc. stock logo
ALT
Altimmune
6/27/2025Reiterated Rating$3.61$12.00Buy
Invivyd, Inc. stock logo
IVVD
Invivyd
6/26/2025Reiterated Rating$0.77$5.00Buy
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
6/24/2025Reiterated Rating$0.50$10.00Buy
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
6/13/2025Reiterated Rating$5.59$75.00Buy
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
6/2/2025Reiterated Rating$38.51$100.00Buy
uniQure N.V. stock logo
QURE
uniQure
5/29/2025Reiterated Rating$15.33$70.00Buy
Invivyd, Inc. stock logo
IVVD
Invivyd
5/28/2025Lower Price Target$0.88$5.00Buy
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
5/21/2025Reiterated Rating$0.43$5.00Buy
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
5/21/2025Reiterated Rating$4.88$60.00Buy
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
5/20/2025Reiterated Rating$1.84$10.00Buy
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
5/20/2025Reiterated Rating$15.74$80.00Buy
Compass Pathways PLC Sponsored ADR stock logo
CMPS
Compass Pathways
5/12/2025Reiterated Rating$3.79$45.00Buy
GH Research PLC stock logo
GHRS
GH Research
5/9/2025Reiterated Rating$10.94$40.00Buy
uniQure N.V. stock logo
QURE
uniQure
4/21/2025Reiterated Rating$13.72$70.00Buy
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
4/8/2025Reiterated Rating$2.93$30.00Buy
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
4/7/2025Reiterated Rating$15.27$80.00Buy
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
4/7/2025Reiterated Rating$0.66$10.00Buy
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
4/7/2025Initiated Coverage$1.87$10.00Buy
Altimmune, Inc. stock logo
ALT
Altimmune
4/3/2025Reiterated Rating$4.61$12.00Buy
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
4/2/2025Reiterated Rating$261.73$500.00Buy
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
3/28/2025Reiterated Rating$4.54$60.00Buy
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
3/28/2025Reiterated Rating$0.95$25.00Buy
Invivyd, Inc. stock logo
IVVD
Invivyd
3/26/2025Reiterated Rating$0.66$10.00Buy
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
3/19/2025Reiterated Rating$1.38$10.00Buy
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
3/19/2025Reiterated Rating$4.91$60.00Buy
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
3/18/2025Reiterated Rating$1.39$10.00Buy
Altimmune, Inc. stock logo
ALT
Altimmune
3/18/2025Reiterated Rating$5.97$12.00Buy
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
3/17/2025Reiterated Rating$2.45$25.00Buy
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
3/13/2025Reiterated Rating$4.06$30.00Buy
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
3/12/2025Reiterated Rating$28.42$100.00Buy
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
3/10/2025Reiterated Rating$24.32$80.00Buy
This is the worst news for stocks in 50 years (Ad)

Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst environment in 50 years - with portfolios potentially staying in the red for 10 years or longer. From rate spikes in 2022 to $12 trillion wiped out in 30 days during the Iran War, Wall Street suggests the volatility isn't slowing down. TradeSmith CEO Keith Kaplan is showing investors what steps to take now to prepare their wealth before this worsens.tc pixel

Click here to learn how to defend your portfolio before this hits
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
3/10/2025Reiterated Rating$0.66$5.00Buy
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
3/7/2025Reiterated Rating$6.61$55.00Buy
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
3/7/2025Reiterated Rating$4.74$75.00Buy
Compass Pathways PLC Sponsored ADR stock logo
CMPS
Compass Pathways
3/4/2025Reiterated Rating$3.75$45.00Buy
uniQure N.V. stock logo
QURE
uniQure
3/4/2025Reiterated Rating$10.76$70.00Buy
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
3/3/2025Reiterated Rating$4.00$30.00Buy
Altimmune, Inc. stock logo
ALT
Altimmune
3/3/2025Reiterated Rating$6.24$12.00Buy
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
2/28/2025Reiterated Rating$27.27$80.00Buy
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
2/28/2025Reiterated Rating$1.75$25.00Buy
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
2/28/2025Reiterated Rating$8.01$110.00Buy
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
2/28/2025Reiterated Rating$29.13$100.00Buy
Invivyd, Inc. stock logo
IVVD
Invivyd
2/24/2025Reiterated Rating$1.43$10.00Buy
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2/24/2025Boost Price Target$252.00$500.00Buy
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
2/19/2025Reiterated Rating$5.63$60.00Buy
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
2/13/2025Reiterated Rating$2.55$10.00Buy
Cybin Inc. stock logo
HELP
Cybin
2/13/2025Lower Price Target$9.36$150.00Buy
Compass Pathways PLC Sponsored ADR stock logo
CMPS
Compass Pathways
2/13/2025Lower Price Target$4.25$45.00Buy
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
2/12/2025Reiterated Rating$18.57$80.00Buy
Altimmune, Inc. stock logo
ALT
Altimmune
2/5/2025Reiterated Rating$6.88$12.00Buy
Invivyd, Inc. stock logo
IVVD
Invivyd
2/4/2025Reiterated Rating$1.06$10.00Buy
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
2/3/2025Reiterated Rating$25.92$80.00Buy
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
2/3/2025Reiterated Rating$0.73$5.00Buy
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
1/31/2025Reiterated Rating$10.31$110.00Buy
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
1/31/2025Reiterated Rating$7.13$55.00Buy
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
1/30/2025Reiterated Rating$0.92$10.00Buy
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
1/29/2025Reiterated Rating$5.28$75.00Buy
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
1/28/2025Reiterated Rating$1.42$10.00Buy
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
1/27/2025Reiterated Rating$5.62$30.00Buy
uniQure N.V. stock logo
QURE
uniQure
1/27/2025Boost Price Target$15.67$70.00Buy
GH Research PLC stock logo
GHRS
GH Research
1/27/2025Reiterated Rating$8.83$40.00Buy
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
1/27/2025Reiterated Rating$33.00$100.00Buy
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
1/27/2025Reiterated Rating$1.16$10.00Buy
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
1/27/2025Reiterated Rating$2.05$25.00Buy
Cybin Inc. stock logo
HELP
Cybin
1/27/2025Reiterated Rating$9.46$190.00Buy
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
1/23/2025Reiterated Rating$19.71$80.00Buy
Altimmune, Inc. stock logo
ALT
Altimmune
1/22/2025Reiterated Rating$6.94$12.00Buy
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
1/13/2025Reiterated Rating$249.59$400.00Buy
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
1/10/2025Reiterated Rating$4.50$60.00Buy
GH Research PLC stock logo
GHRS
GH Research
1/10/2025Reiterated Rating$8.40$40.00Buy